Gtree BNT said Wednesday that it has presented data regarding RGN-259, a dry eye treatment, through its U.S. subsidiary ReGenTree, at the 2018 Association for Research in Vision and Ophthalmology (ARVO) in Hawaii.
The research, headed by Inje University Busan Paik Hospital, compared RGN-259 with conventionally sold products, including Cyclosporine A (Product: Restasis), Diquafosol (Product: Diquas) and Lifitegrast (Product: Xiidra) in an animal study. Some U.S. hospitals, including George Washington University and Wayne State University, also participated in the research.
RGN-259 showed excellent efficacy compared to existing treatments such as anti-inflammation, corneal injury treatment and an increase in tears. The medication also showed improvements in restoring the mucin layer and goblet cell, which are essential for tear film retention.
RGN-259 has proved its excellent patient satisfaction and safety through two large-scale global clinical trials and has also demonstrated rapid therapeutic effects compared to existing treatments. Especially, Thymosin β4 and Tβ4, which are the main components of RGN-259, have various therapeutic mechanisms, including anti-inflammatory effects, and are more suitable for the treating dry eye syndrome, which is a multifactorial disease, while conventional therapeutic agents only provide an anti-inflammatory mechanism.
“The results of the study confirmed the superior therapeutic effect of RGN-259 compared to existing treatments,” a company official said. “We believe that the data will be important for negotiating deals with multi-national pharmaceutical companies.”